Amneal passes US FDA approval for marketing Carmustine for Injection USP in 100 mg/vial
22 October 2018 -

Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Friday the receipt of the US FDA approval for the generic version of BiCNU (carmustine) for injection in 100 mg.

In conjunction, the company plans to launch its Carmustine for Injection in November 2018. Carmustine is a medication used mainly for chemotherapy.

For the 12 months ended August 2018, the US market annual sales for Carmustine for Injection USP in 100 mg/vial is estimated to be about USD84m, according to IQVIA.

Headquartered in Bridgewater, NJ, the specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.